Clinical Trials on Gigantism/Acromegaly

Total 190 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Acromegaly | Pituitary Gigantism

Japan
Eunice Kennedy Shriver National Institute of Child...

Recruiting

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

Cushing Disease | Prolactinoma | Panhypopituitarism | Gigantism/Acromegaly

United States
Medical University of Vienna
Surgebright Gmbh

Recruiting

Human Bone Graft in Epiphysiodesis

Leg Length Differences | Primordial Gigantism

Austria
Barts & The London NHS Trust

Recruiting

Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA

Acromegaly | Gigantism | Familial Isolated Pituitary Adenoma | FIPA | Pituitary Adenoma Predisposition | PAP

United Kingdom
Andrea M. Isidori

Completed

Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy (SUM)

Acromegaly Cardiomyopathy

Italy
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Evaluation of Somatostatin Receptors and GH Receptor Expression on Bone of Acromegalic Patients (ACRO-BONE) (ACRO-BONE)

Evaluation of the Expression of Somatostatin Receptors and GH Receptor on Bone of Acromegalic Patients

Italy
Samsung Medical Center

Not yet recruiting

Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma (MERGE)

Acromegaly Due to Pituitary Adenoma

Korea, Republic of
University of Copenhagen
Odense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University Hospital and other collaborators

Completed

Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor (GA-9)

Acromegaly Due to Pituitary Adenoma

Denmark
Immunwork, Inc.

Not yet recruiting

A Phase 1 Study of TE-8214 Solution in Healthy Volunteers

Acromegaly

Australia
Istituto Auxologico Italiano
Politecnico di Milano

Recruiting

Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study (ACROMORFO)

Acromegaly

Italy
Camurus AB

Completed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (ACROINNOVA 1)

Acromegaly

United States, Spain, United Kingdom, Germany, Russian Federation, Greece, Hungary, Italy, Poland, Turkey
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

Acromegaly

China
Ipsen

Completed

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Acromegaly

Germany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
Unity Health Toronto

Completed

Strict IGF-1 Control in Acromegaly (I-Con)

Acromegaly

Canada
Novartis Pharmaceuticals

Completed

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

Acromegaly

Italy, Australia, Belgium, Germany, Switzerland, United States, France
Crinetics Pharmaceuticals Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

Acromegaly

United States, United Kingdom, Slovakia, Australia, Italy, Hungary, Brazil, Germany, Greece, New Zealand, Poland, Romania, Serbia
Chiasma, Inc.

Unknown

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly (OPTIMAL)

Acromegaly

United States, Israel, Canada, Denmark, Netherlands, New Zealand, Australia, United Kingdom, Hungary, Italy, Poland, Bulgaria, Germany, Latvia, Slovenia, Sweden, Turkey
Tulane University
Chiasma, Inc.

Completed

Acromegaly: Patient And Physician Perspectives

Acromegaly

United States
Ipsen

Withdrawn

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly (PLAN-A)

Acromegaly
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Acromegaly

France, Switzerland
Ono Pharmaceutical Co. Ltd

Completed

Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788 (ONO-5788-02)

Acromegaly

Netherlands
Ipsen

Completed

Description of Sign-and-symptom Associations at Acromegaly Diagnosis. (ACRO-POLIS)

Acromegaly

France
Ipsen

Withdrawn

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Acromegaly

Mexico
Ono Pharmaceutical Co. Ltd

Terminated

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

Acromegaly

United States
Ipsen

Completed

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Acromegaly

France, Germany, Spain, Belgium, Russian Federation, United Kingdom, Italy, Lithuania, Czechia, Romania, Poland, Netherlands
Ipsen

Terminated

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly (DOPAACRO 002)

Acromegaly

Serbia, Belgium, Hungary, Ukraine
Ipsen

Completed

Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery (ESPORA)

Acromegaly

Spain
Ipsen

Terminated

Predictive Factors Study (TAPAS)

Acromegaly

Australia
Ipsen

Completed

One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma

Acromegaly

United Kingdom, France, Italy, Czechia, Germany, Turkey
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Acromegaly

United States, Germany, Italy, Belgium, Taiwan, Turkey, Switzerland, Israel, Netherlands, Sweden, United Kingdom, Korea, Republic of, Spain, France, Canada, Greece, Russian Federation, Denmark, Mexico, China, Hungary, Norway, Argentina and more
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients (HOSCAR)

Acromegaly

Italy, France, Portugal, Poland, Switzerland
University of Aarhus
Odense University Hospital; Aarhus University Hospital; Herlev Hospital; Aalborg... and other collaborators

Completed

Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

Acromegaly

Denmark
Erasmus Medical Center
Novartis

Unknown

Pasireotide LAR and Pegvisomant Study in Acromegaly (PAPE)

Acromegaly

Netherlands
Italfarmaco

Completed

Phase II Study With ITF2984 in Acromegalic Patients (POC)

Acromegaly

France, Hungary, Netherlands, Serbia, Czech Republic, Italy, Spain, Poland, Romania
Rigshospitalet, Denmark

Completed

Fractionated Stereotactic Radiotherapy in Patients With Acromegaly

Acromegaly

Denmark
TC Erciyes University

Unknown

Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly (AIP)

Acromegaly

Turkey
Endo Pharmaceuticals

Completed

Open Label Study of Octreotide Implant in Patients With Acromegaly

Acromegaly
Federal University of São Paulo

Completed

Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

Acromegaly

Brazil
Pfizer

Completed

Non Interventional Study For Patients Treated With Somavert® (GPOS)

Acromegaly
Pfizer

Completed

Pegvisomant And Sandostatin LAR Combination Study

Acromegaly

Canada, United States, Germany, Italy, United Kingdom, Norway, Australia, Spain, Brazil, Mexico, France, Netherlands
Pfizer

Recruiting

Korean Regulatory Post Marketing Surveillance for Somavert

Acromegaly

Korea, Republic of
University Hospital, Montpellier

Recruiting

Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients

Acromegaly

France
Ginkgo Leaf Center for Rare Disorders

Recruiting

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

Acromegaly

China
National Taiwan University Hospital

Recruiting

Developing a Simple Recognition System of Acromegaly

Acromegaly

Taiwan
Cedars-Sinai Medical Center

Active, not recruiting

Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly

Acromegaly

United States
Camurus AB

Active, not recruiting

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Acromegaly

United States, Spain, United Kingdom, Germany, Russian Federation, Greece, Hungary, Italy, Poland, Turkey, Serbia
Crinetics Pharmaceuticals Inc.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-1)

Acromegaly

United States, Argentina, Belgium, Brazil, Bulgaria, France, Hungary, Israel, Italy, Peru, Poland, Russian Federation, Serbia, United Kingdom
Crinetics Pharmaceuticals Inc.

Active, not recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

Acromegaly

United States, Hungary, Brazil, Greece, Serbia, United Kingdom
University of Aarhus

Active, not recruiting

ACRODAT Prospective Evaluation Study

Acromegaly

Denmark
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly

Acromegaly

United States, Hungary, Serbia, Estonia, Italy, Latvia, Lithuania, Poland, Romania, Russian Federation

Clinical Trials on Gigantism/Acromegaly

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations